Most procurement heads at pharmaceutical companies will say that their budget is under control if you ask them. However, the story changes as you examine it more attentively. Small vendor purchases that never get consolidated. A single overseas supplier quietly controlling the price of a critical ingredient. Forecasts built on last year’s numbers instead of this year’s market. None of it looks alarming on its own. But add it up over a few quarters, and you’re staring at real money walking out the door. The companies getting ahead of this aren’t cutting costs harder — they’re just finally seeing where it’s going.